Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Anti-interleukin-5 therapy (mepolizumab) in life-threatening asthma attack: A case-based discussion.

Tello K, Hoffmann A, Beutel B, Greulich T, Vogelmeier CF, Richter MJ, Kuhnert S, Böselt T, Alter P, Holland A, Idzko M, Buhl R, Koczulla AR.

Respir Med Case Rep. 2019 Aug 22;28:100927. doi: 10.1016/j.rmcr.2019.100927. eCollection 2019.

2.

Anti-IL5 therapies for asthma.

Farne HA, Wilson A, Powell C, Bax L, Milan SJ.

Cochrane Database Syst Rev. 2017 Sep 21;9:CD010834. doi: 10.1002/14651858.CD010834.pub3. Review.

3.

Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study.

Pelaia C, Busceti MT, Solinas S, Terracciano R, Pelaia G.

Pulm Pharmacol Ther. 2018 Dec;53:1-5. doi: 10.1016/j.pupt.2018.09.006. Epub 2018 Sep 11.

PMID:
30217438
5.

Mepolizumab treatment in patients with severe eosinophilic asthma.

Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW, Chanez P; MENSA Investigators.

N Engl J Med. 2014 Sep 25;371(13):1198-207. doi: 10.1056/NEJMoa1403290. Epub 2014 Sep 8. Erratum in: N Engl J Med. 2015 Apr 30;372(18):1777.

6.

Mepolizumab versus placebo for asthma.

Powell C, Milan SJ, Dwan K, Bax L, Walters N.

Cochrane Database Syst Rev. 2015 Jul 27;(7):CD010834. doi: 10.1002/14651858.CD010834.pub2. Review. Update in: Cochrane Database Syst Rev. 2017 Sep 21;9:CD010834.

PMID:
26214266
7.

Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.

Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, Trevor JL, Magnan A, Ten Brinke A.

Lancet Respir Med. 2017 May;5(5):390-400. doi: 10.1016/S2213-2600(17)30125-X. Epub 2017 Apr 5.

PMID:
28395936
8.

Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study.

Khurana S, Brusselle GG, Bel EH, FitzGerald JM, Masoli M, Korn S, Kato M, Albers FC, Bradford ES, Gilson MJ, Price RG, Humbert M.

Clin Ther. 2019 Oct;41(10):2041-2056.e5. doi: 10.1016/j.clinthera.2019.07.007. Epub 2019 Aug 22.

9.

Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study.

Lugogo N, Domingo C, Chanez P, Leigh R, Gilson MJ, Price RG, Yancey SW, Ortega HG.

Clin Ther. 2016 Sep;38(9):2058-2070.e1. doi: 10.1016/j.clinthera.2016.07.010. Epub 2016 Aug 21.

10.

Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype.

Basu A, Dalal A, Canonica GW, Forshag M, Yancey SW, Nagar S, Bell CF.

Expert Rev Pharmacoecon Outcomes Res. 2017 Apr;17(2):121-131. doi: 10.1080/14737167.2017.1298444. Epub 2017 Mar 17.

PMID:
28277854
11.

Efficacy and safety of mepolizumab in a real-world cohort of patients with severe eosinophilic asthma.

Pertzov B, Unterman A, Shtraichman O, Shitenberg D, Rosengarten D, Kramer MR.

J Asthma. 2019 Sep 3:1-6. doi: 10.1080/02770903.2019.1658208. [Epub ahead of print]

PMID:
31479312
12.

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.

Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG, Pavord ID; SIRIUS Investigators.

N Engl J Med. 2014 Sep 25;371(13):1189-97. doi: 10.1056/NEJMoa1403291. Epub 2014 Sep 8.

13.

Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Bermejo I, Stevenson M, Cooper K, Harnan S, Hamilton J, Clowes M, Carroll C, Harrison T, Saha S.

Pharmacoeconomics. 2018 Feb;36(2):131-144. doi: 10.1007/s40273-017-0571-8. Review.

14.

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.

Ortega HG, Yancey SW, Mayer B, Gunsoy NB, Keene ON, Bleecker ER, Brightling CE, Pavord ID.

Lancet Respir Med. 2016 Jul;4(7):549-556. doi: 10.1016/S2213-2600(16)30031-5. Epub 2016 May 10.

PMID:
27177493
15.

Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma.

Shimoda T, Odajima H, Okamasa A, Kawase M, Komatsubara M, Mayer B, Yancey S, Ortega H.

Allergol Int. 2017 Jul;66(3):445-451. doi: 10.1016/j.alit.2016.11.006. Epub 2017 Jan 16.

16.

Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment.

Magnan A, Bourdin A, Prazma CM, Albers FC, Price RG, Yancey SW, Ortega H.

Allergy. 2016 Sep;71(9):1335-44. doi: 10.1111/all.12914. Epub 2016 May 24.

17.

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.

Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P.

Lancet. 2012 Aug 18;380(9842):651-9. doi: 10.1016/S0140-6736(12)60988-X.

PMID:
22901886
18.

Pharmacokinetic drug evaluation of mepolizumab for the treatment of severe asthma associated with persistent eosinophilic inflammation in adults.

Kallur L, Gonzalez-Estrada A, Eidelman F, Dimov V.

Expert Opin Drug Metab Toxicol. 2017 Dec;13(12):1275-1280. doi: 10.1080/17425255.2017.1406919. Review.

PMID:
29157020
19.

Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.

Pelaia C, Vatrella A, Busceti MT, Gallelli L, Terracciano R, Savino R, Pelaia G.

Drug Des Devel Ther. 2017 Oct 30;11:3137-3144. doi: 10.2147/DDDT.S150656. eCollection 2017. Review.

20.

Clinical efficacy of anti-IL-5 monoclonal antibody mepolizumab in the treatment of eosinophilic otitis media.

Iino Y, Takahashi E, Ida S, Kikuchi S.

Auris Nasus Larynx. 2019 Apr;46(2):196-203. doi: 10.1016/j.anl.2018.07.011. Epub 2018 Aug 16.

PMID:
30122651

Supplemental Content

Support Center